ホーム>>Signaling Pathways>> GPCR/G protein>> Prostaglandin Receptor>>SQ 29,548

SQ 29,548

カタログ番号GC15213

高親和性放射性リガンドである SQ 29,548 は、選択的トロンボキサン-プロスタノイド (TP) 受容体アンタゴニストです。

Products are for research use only. Not for human use. We do not sell to patients.

SQ 29,548 化学構造

Cas No.: 98672-91-4

サイズ 価格 在庫数 個数
1mg
$140.00
在庫あり
5mg
$594.00
在庫あり
10mg
$1,048.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SQ 29,548 is a novel and selective thromboxane antagonist [1]. Thromboxane belongs to a family of lipids involved in clot formation (thrombosis). Thromboxane is a vasoconstrictor and a potent hypertensive agent which facilitates platelet aggregation [2].

In vitro: In guinea-pig trachea and rat aorta, SQ 29,548 competitively antagonized the activity of 9,11-azo PGH2 with pA2 values of 7.8 and 8.4, respectively. SQ 29,548 competitively antagonized contractions of guinea-pig tracheal spirals induced by 11,9-epoxymethano PGH2 with the pA2 value of 9.1. The SQ 29,548 competitively antagonized tracheal induced by 11,9-epoxymethano PGH2 and PGD2 with the pA2 values of 8.2 and 8.3, respectively. SQ 29,548 partially antagonized the contractions of guinea-pig tracheal spirals caused by PGE2. SQ 29,548 significantly inhibited the aorta contracting activity of 11,9-epoxymethano PGH2 (pA2 = 9.1) and thromboxane A2 released from perfused guinea-pig lungs upon arachidonic acid challenge [1].

In vivo: In anesthetized dogs, SQ 29,548 (0.2 mg/kg/h) completely inhibited the vasoconstrictor response of the left circumflex coronary artery (LCX) caused by U-46619. SQ 28,585 showed no effects on infarct size as compared with vehicle controls [3]. In sham MI rats, treatment with SQ-29,548 significantly blunted this loss of CK activity and amino-nitrogen concentration from the ischemic myocardium. SQ-29,548 significantly prevented the extension of ischemic damage in the myocardium and improved survival following acute coronary artery ligation [4].

References:
[1] Ogletree M L, Harris D N, Greenberg R, et al.  Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist[J]. Journal of Pharmacology and Experimental Therapeutics, 1985, 234(2): 435-441.
[2] Abe T, Takeuchi K, Takahashi N, et al.  Rat kidney thromboxane receptor: molecular cloning, signal transduction, and intrarenal expression localization[J]. Journal of Clinical Investigation, 1995, 96(2): 657.
[3] Grover G J, Schumacher W A.  Effect of the thromboxane receptor antagonist SQ 29,548 on myocardial infarct size in dogs[J]. Journal of cardiovascular pharmacology, 1988, 11(1): 29-35.
[4] Hock C E, Brezinski M E, Lefer A M.  Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia[J]. European journal of pharmacology, 1986, 122(2): 213-219.

レビュー

Review for SQ 29,548

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SQ 29,548

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.